Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Importance Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design This retrospective case control study with a test-negative design was conducted during the 2024–2025 and 2025–2026 RSV seasons. Setting Enrollment was in 26 hospitals across 24 U.S. states. Participants Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8−23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures Receipt of nirsevimab before or during the child’s second RSV season and at least 7 days before symptom onset. Outcomes and measures RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population. Key Points Question : What is the effectiveness of nirsevimab against RSV-associated hospitalizations among children 8-23 months old who are at risk for severe disease and in their second RSV season? Findings: In this case-control study of hospitalizations for acute respiratory illness among high-risk children in their second RSV season, receipt of nirsevimab was associated with an estimated 78% reduction in risk of RSV-associated hospitalizations. Meaning : Nirsevimab provided substantial protection against RSV-associated hospitalizations in children at high risk of severe RSV during their second RSV season.
Source: medRxiv
Authors: Regina M. Simeone, Margaret M. Newhams, Amanda B. Payne, Amber O. Orzel-Lockwood, Jemima Calixte, Natasha B. Halasa, Satoshi Kamidani, Hillary Crandall, Katherine Irby, Aline B. Maddux, Danielle M. Zerr, Judith A. Guzman-Cottrill, Jennifer E. Schuster, Kathleen Chiotos, Michele Kong, Mary Allen Staat, Janet R. Hume, Melissa S. Stockwell, Melissa A. Cameron, Alexander H. Hogan, Jigar C. Chauhan, Austin Biggs, Emily R. Levy, Samina S. Bhumbra, Tracie C. Walker, Neelima K. Marupudi, Mary K. Prahl, Kelly N. Michelson, Lora M. Martin, Tamara T. Bradford, Adrienne G. Randolph, Angela P. Campbell
Institutions: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Boston Children's Hospital, Vanderbilt University Medical Center, Emory University, Children's Healthcare of Atlanta, Primary Children's Hospital, University of Utah, Arkansas Children's Hospital, Children's Hospital Colorado, University of Colorado Anschutz, University of Washington, Seattle Children's Research Institute, Oregon Health & Science University, Children's Mercy Hospital, University of Missouri–Kansas City, Children's Hospital of Philadelphia, University of Alabama at Birmingham, Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Minnesota, Columbia University, University of California San Diego, Rady Children's Hospital-San Diego, Connecticut Children's Medical Center, Medical University of South Carolina, Mayo Clinic, Indiana University School of Medicine, University of North Carolina at Chapel Hill, University of North Carolina Hospitals, University of Arizona, Banner Desert Medical Center, Banner Children's at Desert, University of California, San Francisco, Lurie Children's Hospital, University of Mississippi Medical Center, Louisiana State University, Children's Hospital of New Orleans, Louisiana State University Health Sciences Center New Orleans, Harvard University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Award: G2491226629
OpenAlex ID: W7234292779
